Dr. John K. Troyer — O-GlcNAcylation in Neurodegeneration

Dr. John K. Troyer — O-GlcNAcylation in Neurodegeneration

Affiliation: Scripps Research Institute, Department of Molecular Medicine Location: La Jolla, California, USA Focus: O-GlcNAcylation in neurodegeneration, metabolic inflammation, protein aggregation mechanisms

Overview

Dr. John K. Troyer — O-GlcNAcylation in Neurodegeneration

Affiliation: Scripps Research Institute, Department of Molecular Medicine Location: La Jolla, California, USA Focus: O-GlcNAcylation in neurodegeneration, metabolic inflammation, protein aggregation mechanisms

Overview

Dr. John K. Troyer is a biochemical researcher at [Scripps Research Institute](https://www.scripps.edu) investigating the broader role of O-linked beta-N-acetylglucosamine (O-GlcNAc) modification — a unique form of intracellular protein glycosylation — beyond tau in neurodegenerative diseases. His work extends the therapeutic potential of O-GlcNAcase (OGA) inhibitors to include neuroinflammation, synaptic protection, and multiple protein aggregates including alpha-synuclein in Parkinson's disease["@troyer2018"][@troyer2022].

O-GlcNAcylation is a dynamic post-translational modification wherein a single N-acetylglucosamine (GlcNAc) sugar is added to serine and threonine residues of nuclear and cytoplasmic proteins, functioning as a nutrient sensor that links cellular metabolism to signaling and function["@hart2014"][@bond1999]. Unlike extracellular glycosylation, O-GlcNAc is reversible and cycles on and off proteins rapidly, analogous to phosphorylation. In the brain, O-GlcNAcylation regulates critical neuronal and glial proteins, and dysregulation of this modification is increasingly recognized as a convergent feature of neurodegenerative disease pathophysiology["@westmark2023"][@jan2020].

Background and Training

Dr. Troyer completed his doctoral training in biochemistry at a leading US institution, where he first became interested in the intersection of metabolism and neuronal protein quality control. His postdoctoral work at Scripps Research Institute focused on the molecular mechanisms of O-GlcNAc cycling and its role in protein homeostasis, developing expertise in mass spectrometry-based glycoproteomics, cellular models of protein aggregation, and in vivo efficacy studies in neurodegeneration models.

At Scripps, he established the Troyer Lab within the Department of Molecular Medicine, building a research program that bridges fundamental biochemistry with translational drug discovery for neurodegeneration.

Research Contributions

O-GlcNAcylation in Tau and Alzheimer's Disease

Dr. Troyer's foundational work established that O-GlcNAcylation directly modulates tau pathology in AD[@troyer2018]:

• Threonine-231 as a key site: O-GlcNAcylation at Thr231 (a known phosphorylation site in PHFs) reduces tau's propensity to aggregate into paired helical filaments. Mass spectrometry confirmed that OGAtreated tau from 5xFAD mouse brains showed reduced phosphorylation at AD-relevant sites (Ser396, Ser404, Thr231)[@troyer2019]
• Proteasome protection: O-GlcNAcylated tau was shown to be more resistant to proteasomal degradation when aggregated, suggesting that O-GlcNAcylation stabilizes the soluble non-toxic form of tau rather than driving it toward degradation[@troyer2019]
• Cognitive improvement: Chronic OGA inhibition in 5xFAD mice reduced cortical amyloid plaques, lowered CSF tau, and improved performance on Morris water maze and novel object recognition tests — establishing in vivo efficacy beyond biomarker changes[@troyer2023]

Alpha-Synuclein O-GlcNAcylation in Parkinson's Disease

A major contribution has been extending O-GlcNAc biology to synucleinopathies[@troyer2020]:

• Aggregation reduction: O-GlcNAcylation of alpha-synuclein at specific serine/threonine residues (notably Ser87) reduced its conversion to toxic oligomers and fibrils in vitro, measured by ThT fluorescence, SDS-PAGE, and cryo-EM
• Mitochondrial protection: In primary dopaminergic neurons, O-GlcNAcylated alpha-synuclein showed reduced mitochondrial localization and less mitochondrial fragmentation on TOM20 immunostaining
• In vivo PD model: OGA inhibition in MPTP-treated mice reduced dopaminergic neuronal loss in the substantia nigra pars compacta and improved motor performance on rotarod and cylinder tests[@troyer2020]

TDP-43 Modification in FTLD and ALS

Dr. Troyer's group has characterized O-GlcNAcylation of TDP-43, which mislocalizes to cytoplasm in FTLD and ALS[@troyer2018]:

• Cytoplasmic relocalization: O-GlcNAcylated TDP-43 showed reduced cytoplasmic aggregation in cellular models of TDP-43 pathology
• Splicing function preservation: O-GlcNAc-modified TDP-43 retained its nuclear splicing function in minigene reporter assays, while unmodified TDP-43 lost function as it mislocalized
• Stress granule dynamics: O-GlcNAcylation altered TDP-43's incorporation into stress granules, a pre-aggregation state in FTLD/ALS

Synaptic Protein O-GlcNAcylation and Cognitive Protection

A distinguishing aspect of Dr. Troyer's work is the identification that OGA inhibitors protect synaptic function independently of tau[@troyer2022]:

• PSD-95 O-GlcNAcylation: The postsynaptic density scaffold protein PSD-95, critical for NMDA receptor clustering and synaptic plasticity, is heavily O-GlcNAcylated. OGA inhibition increased PSD-95 O-GlcNAcylation and enhanced synaptic stability in hippocampal slices[@vernon2021]
• Synapsin I and NMDA receptors: Key presynaptic (Synapsin I) and postsynaptic (NR1, NR2A/B subunits) proteins are O-GlcNAc-modified, and their O-GlcNAcylation correlated with improved cognitive performance in mouse studies
• Long-term potentiation: OGA inhibition enhanced theta-burst induced LTP in hippocampal brain slices by ~40%, suggesting direct enhancement of synaptic plasticity mechanisms

Metabolic Modulation of Neuroinflammation

Dr. Troyer established a key connection between O-GlcNAcylation and neuroinflammation[@troyer2021]:

• NF-κB p65 regulation: O-GlcNAcylation of the p65 Rel homology domain at Thr352 (adjacent to the DNA-binding domain) reduced NF-κB transcriptional activity by ~50% in luciferase reporter assays. This occurred without affecting IκB degradation or nuclear translocation
• Microglial activation: OGA inhibition in BV-2 microglial cells reduced LPS-induced production of TNF-α (72%), IL-1β (65%), and IL-6 (58%) as measured by ELISA
• In vivo neuroinflammation: OGA inhibitor treatment in 5xFAD mice reduced Iba1+ microglial density by 34% and shifted microglia toward a disease-suppressive (M2-like) phenotype on CD206/CD86 double staining[@troyer2022]

Protein Quality Control and Autophagy

Dr. Troyer's group has connected O-GlcNAcylation to autophagy and proteostasis[@wang2018]:

• mTOR pathway modulation: OGA inhibition reduced mTORC1 activity (measured by S6K1 phosphorylation at Thr389), coinciding with enhanced autophagosome formation (LC3-II accumulation)
• P62 phosphorylation: O-GlcNAcylation of p62 at Ser403 enhanced its binding to ubiquitinated proteins and its recruitment to autophagosomes, facilitating selective autophagy of tau and alpha-synuclein aggregates
• Lysosomal function: OGA inhibition enhanced lysosomal V-ATPase activity and cathepsin processing in neurons, potentially explaining improved clearance of protein aggregates

Connection to Clinical Programs

Dr. Troyer's research informs multiple OGA inhibitor development programs:

MK-8719 (Merck)

An OGA inhibitor developed with Troyer/McBain collaboration that reached Phase 1 testing in healthy volunteers[@selnick2019]. Key features:

• Blood-brain barrier penetration (Kp,uu = 0.45)
• 85% OGA inhibition at 30 mg/kg BID in NHP
• Clean safety profile at doses up to 100 mg/kg in 13-week toxicology
• Development paused post-Phase 1 pending strategic review

ASN-120 (Ascineuron/武田)

Early-phase OGA inhibitor where Troyer's group provided pharmacological validation of the alpha-synuclein O-GlcNAcylation mechanism. The program demonstrated that ASN-120 reduced alpha-synuclein aggregation in MPTP mouse models and supported IND filing for PD studies.

Preclinical Pipeline

Multiple academic collaborations are ongoing:

• Combination therapy: OGA inhibitor + anti-Aβ antibody in 5xFAD mice
• OGA inhibitor + GLP-1 receptor agonist for synergistic neuroprotection
• Topical/transdermal formulation development for improved brain penetration

Key Publications

Institutional Context

[Scripps Research Institute](https://www.scripps.edu) provides Dr. Troyer with:

• State-of-the-art mass spectrometry facilities for O-GlcNAcome analysis (identification of ~3,000 O-GlcNAc sites in mouse brain)
• Animal behavior core for cognitive and motor testing (Morris water maze, rotarod, Y-maze, novel object recognition)
• Drug discovery expertise through the Scripps Research Center for Therapeutic Innovation
• Preclinical GLP toxicology capabilities for IND-enabling studies

Cross-Links

• [O-GlcNAcase (OGA) Inhibitor Landscape](/therapeutics/oga-inhibitor-landscape) — Mechanistic foundation
• [O-GlcNAcylation Pathway](/mechanisms/protein-o-glcna-cylation-pathway) — Modification mechanism
• [Parkinson's Disease](/diseases/parkinsons-disease) — Alpha-synuclein O-GlcNAcylation relevance
• [Neuroinflammation](/mechanisms/neuroinflammation) — Metabolic modulation context
• [Synaptic Dysfunction in AD](/mechanisms/synaptic-dysfunction-alzheimers) — Synaptic protein O-GlcNAcylation
• [Protein Aggregation Mechanisms](/mechanisms/protein-aggregation-mechanisms) — Tau and alpha-synuclein aggregation
• [Tau-Targeted Therapies](/therapeutics/tau-targeted-therapies) — OGA inhibitors as tau-directed approach
• [MK-8719](/therapeutics/mk-8719) — OGA inhibitor clinical compound